July 07, 2026

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.

Conexiant

July 07, 2026

More Physicians Enter Politics

Viewpoint explores how more physician-candidates could reshape both public service and public trust in medicine.

Conexiant

July 06, 2026

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

Conexiant

July 01, 2026

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

Conexiant

July 01, 2026

PTSD May Be Linked to Accelerated Aging

Integrated proteomic and metabolomic analyses identified redox-metabolic signatures associated with chronic posttraumatic stress disorder and accelerated biological aging across multiple organ systems.

Conexiant

July 01, 2026

NEJM Retracts Avacopan Vasculitis Study

"The primary end-point assessments in nine patients were readjudicated after database lock and trial unblinding"

Conexiant

June 29, 2026

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

Conexiant

June 29, 2026

Measles-Related Vitamin A Searches Rise

Google Trends data showed increased US search interest in vitamin A and cod liver oil during the 2025 measles outbreak, but normalized search data cannot determine actual product use, dosing behavior, or harms.

Conexiant

June 26, 2026

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

Conexiant

June 26, 2026

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant